Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study

Journal of Clinical Pharmacy and Therapeutics

Volumn 41, Issue 5, 2016, Pages 532-537

  Mladenovic Antic, S ^a   Kocic, B ^a,b   Velickovic Radovanovic, R ^b,c   Dinic, M ^a,b   Petrovic, J ^c   Randjelovic, G ^a,b   Mitic, R ^c  

^a Institute for Public Health of Nis   (Serbia)

^b UNIVERSITY OF NI   (Serbia)

^c Clinical Centre of Ni   (Serbia)

Author keywords

antibiotic utilization; antimicrobial resistance; carbapenems; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG USE; HOSPITAL INFECTION; HUMAN; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SERBIA; TERTIARY CARE CENTER; TREND STUDY;

EID: 84983238397     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12432     Document Type: Article

References (31)

1. Huttner A, Harbarth S, Carlet J et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control, 2013;2:31. eCollection 2013.
2. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: CDC, 2013. Available from: www.cdc.gov/drugresistance/threat-report-2013
3. Camins BC, King MD, Wells JB, Googe HL, Patel M, Kourbatova EV, Blumberg HM. Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. Infect Control Hosp Epidemiol, 2009;30:931–938.
4. Velickovic– Radovanovic R, Stefanovic N, Damnjanovic I et al. Monitoring of antibiotic consumption and development of resistance by enterobacteria in a tertiary care hospital. J Clin Pharm Ther, 2015;40:426–430.
5. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis, 2009;48:1–12.
6. Zhanel G, Decorby M, Adam H et al. Prevalence of antimicrobial- resistant pathogens in canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother, 2010;54:4684–4693.
7. Mahar P, Padiglione AA, Cleland H, Paul E, Hinrichs M, Wasiak J. Pseudomonas aeruginosa bacteraemia in burns patients: risk factors and outcomes. Burns, 2010;36:1228–1233.
8. Strateva T, Yordanov D. Pseudomonas aeruginosa – a phenomenon of bacterial resistance. J Med Microbiol, 2009;58:1133–1148.
9. Lister PD, Wolter DJ, Hanson ND. Antibacterial Resistant Pseudomonas aeruginosa: clinical cmpact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev, 2009;22:582–610.
10. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs, 2007;67:351–368.
11. WHO. (2005) ATC index with DDDs. World Health Organisation Collaborating Centre for Drug Statistics Methodology; 2003–2005. Available at: http://www.whocc.no/atcddd_publications/guidelines/ (accessed 25 April 2009).
12. Clinical and Laboratory Standards Insitute. Performance standards for antimicrobial susceptebility testing: twenty-third informational supplement M100-S23. Wayne, PA, USA: CLSI, 2013.
13. Consumption of Antibacterials For Systemic Use (ATC group J01) in the hospital sector in Europe, reporting year 2014. Available from: http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/esac-net-database/ (accessed 25 July 2016).
14. European Centre for Disease Prevention and Control. EARS-Net Reporting Protocol. July 2015. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Documents/2015-EARS-et-reporting-protocol.pdf/ (accessed 25 July 2016).
15. Messadi AA, Lamia T, Kamel B, Salima O, Monia M, Saida BR. Association between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in an intensive care burn unit: a 5-year study, 2000–2004. Burns, 2008;34:1098–1102.
16. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother, 2002;46:2920–2925.
17. Velickovic-Radovanovic R, Petrovic J, Kocic B, Antic S, Mitic R. Analysis of antibiotic utilization and bacterial resistance changes in a surgical clinic of Clinical Centre, Nis. J Clin Pharm Ther, 2012;37:32–36.
18. Medic D, Mihajlovic- Ukropina M, Gusman V, Jelesic Z, Milosavljevic B. Carbapenems resistance of Acinetobacter spp. strains isolated from wound swabs during 2009-2010. Med Pregl, 2011;12:583–587.
19. Stanković-Nedeljković N, Tiodorović B, Kocić B, Ćirić V, Milojković M, Waisi H. Pseudomonas aeruginosa serotypes and resistance to antibiotics from wound swabs. Vojnosanit Pregl, 2015;72:996–1003.
20. Central Asian and Eastern European Surveillance of Antimicrobial Resistance. Annual report 2014. available from:http://www.euro.who.int/en/health-topics/disease-prevention/antimicrobial-resistance/publications/2015/central-asian-and-eastern-european-surveillance-of-antimicrobial-resistance.-annual-report-2014/ (accessed 25 July 2016).
21. Sardelić S, Bedenić B. Rezistencija na antibiotike u Pseudomonas aeruginosa. Croatian J Infect, 2009;29:4, 177–183 ISSN 1331-2820 UDK 579.841.1:615.33.
22. Yayan J, Ghebremedhin B, Rasche K. Antibiotic resistance of Pseudomonas aeruginosa in pneumonia at a Single University Hospital Center in Germany over a 10-year period. PLoS ONE, 2015;10:e0139836.
23. Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents, 2005;26:463–472.
24. Kallel H, Mahjoubi F, Dammak H et al. Correlation between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a medical-surgical intensive care unit. Indian J Crit Care Med, 2008;12:18–23.
25. Mouawad R, Afif C, Azar E, Dahdouh E, Masri K, Irani J, Daoud Z. Effect of antibiotic consumption on resistance of Pseudomonas aeruginosa isolated from Lebanese patients with emphasis on MBL production. Adv Microbiol, 2013;3:382–388.
26. Goel N, Wattal C, Oberoi JK, Raveendran R, Datta S, Prasad KJ. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J Antimicrob Chemother, 2011;66:1625–1630.
27. Patzer JA, Dzierzanowska D, Turner PJ. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYS TIC programme (1997–2007). J Antimicrob Chemother, 2008;62:369–375.
28. Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents, 2001;17:357–363.
29. Willemsen I, Bogaers-Hofman D, Winters M, Kluytmans J. Correlation between antibiotic use and resistance in a hospital: temporary and ward-specific observations. Infection, 2009;37:432–437.
30. Sixty-eighth World Health Assembly Available from: http://www.who.int/drugresistance/global_action_plan/en/ (accessed 25 July 2016).
31. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis, 2007;44:159–177.